Bids process to share in £3 million Cystic Fibrosis funds opens
20 Mar 2023
Applications are invited for a share of £3 million investment to accelerate the development of new treatments for people with Cystic Fibrosis.
Cystic Fibrosis Syndicate in Antimicrobial Resistance’s (CF AMR) Collaborative Discovery Programme is funded by medical research charity to support around five collaborative projects that aim to treat chronic respiratory infections in sufferers.??
The process is open to academic projects as well as small and medium enterprises (SMEs) throughout the world and can last up to two years.
To qualify, entrants must address patient priorities for improving treatment as described within the CF AMR Target Product Profiles for Antimicrobials.
Up to £500,000 will be available per successful applicant. The CF AMR syndicate website opens for expressions of intent on 30 March and closes 9 May 2023.? cfamr.org.uk
Successful applicants will be able to tap into advice and support from the project’s managing partners, Medicines Discovery Catapult, LifeArc and the Cystic Fibrosis Trust.?
Part of LifeArc’s overall £100 million programme to accelerate scientific innovation for people living with CF and bronchiectasis and working with MDC and Cystic Fibrosis Trust, the funding scheme aims “to deliver new therapies to end the vicious cycle of infection, inflammation and permanent lung damage for people living with CF,"? said LifeArc Chronic Respiratory Infection Translational Challenge Lead Dr Catherine Kettleborough.
Head of Research at Cystic Fibrosis Trust Dr Paula Sommer said CF sufferers were particularly vulnerable to antimicrobial resistance, hence the need for new antimicrobials that target these.
Pic: Robina Weermeijer
